Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men with obstructive symptoms due to benign prostatic hyperplasia who are also on anticoagulant regimen.~* Anticoagulant regiments include: Aspirin 81mg, Aspirin 325mg, Adenosine diphosphate (ADP) receptor inhibitors, Cilostazol, Dabigatran, Dipyridamole, or Warfarin. The patient will be stable on their dosage regimen for at least 3 months.~* Maximum flow rate \<15ml/s by uroflowmetry.~* International Prostate Symptom Score (IPSS)≥10.~Exclusion Criteria:~* Patients with coagulopathy, INR exceeding 3.~* Anti-coagulation dose changes within 3 months of surgery.~* Patients not medically cleared to undergo surgery for medical reasons.~* Patients with neurogenic bladder (bladder affected due to a neurologic cause).~* Urethral stricture, obstruction due to stricture.~* Suspected bladder or prostate cancer.~* Prostate size greater than 80 cc.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BPH on anticoagulation (Type: None): Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication

Based on this trial design, predict the completion outcome and termination type (if applicable).